Sponsored by   Mudabala
 
 
BETA
Loading Loading ...
Sat, 20 Mar 2010 | 18:08 GMT
Sat, Mar 20, 2010, 18:08 GMT
 

Evolvence to invest in Indian pharmaceutical companies

Emirates Business 24/7
 
 
Emirates Business 24-7, 06 July 2009

Dubai-based Evolvence CapitalEvolvence CapitalLoading... has recently invested about Dh19.2 million in an Indian pharmaceutical company and plans two or three more investments in the coming months, said senior officials of the company.

"We are investing into pharmaceutical companies in India. And we are investing with a long-term perspective. India will attract a lot of pharmaceutical research as costs are significantly lower when compared to the West," CEO Khaled Al Muhairy told Emirates Business.

Evolvence CapitalEvolvence CapitalLoading... will be investing in India through one of its Indian arm, the Evolvence India Lifestyle Fund (EILF).

The fund recently invested Dh19.2m in Chennai-based pharmaceutical company, Anjan Drugs, one of the largest Food and Drug Authority approved manufacturers of drugs for epilepsy.

Anjan specialises in medicines used for the treatment of nervous system disorders. Last year, EILSF invested $30 million (Dh110m) in Hyderabad-based advanced drug delivery mechanism company, Gland Pharma. EILSF also invested $5m in Bangalore-based cancer centre network, Health Care Global.

Hari Buggana, Managing Director of EILSF, said the company is currently performing due diligence on a couple of more companies and will make announcements in this regard in the next few months.

Evolvence CapitalEvolvence CapitalLoading... that plans to invest $ 100m in the pharmaceutical research in India is also looking forward to invest in medical devices, Crams (contract research and manufacturing services), diagnostics, and speciality healthcare services. The company plans two to three deals worth $20m to $25m in India this year.

"We are targeting companies that export from India to the US," said Muhairy.

Evolvence capital expects Anjan Drugs sales to "at least quadruple" this year and "we also see the Chennai-based company launching three other products. Investments in the company are being made in tranches".

Muhairy, who handled Abu Dhabi Investment Authority's (Adia) investments in technology in North America prior to launching Evolvence CapitalEvolvence CapitalLoading..., said he is particularly interested in high-end research projects.

The company's investment strategy in pharmaceutical companies in India would only be growth capital for minority stakes, said Buggana recently. "We did not raise this fund by positioning it as a buyout fund."

By Shashank Shekhar

© Emirates Business 24/7 2009

 
x DISCLAIMER

Zawya is a distributor (and not a publisher) of content supplied by third parties and subscribers. Any opinions, advice, statements, services, offers, or other information or content expressed or made available by those third parties, including information providers, subscribers or other users of the Service, are those of the respective author(s) or distributor(s) and not of the Company. The Company neither endorses nor is responsible for the accuracy or reliability of any opinion, advice or statement made on the Service by anyone other than authorized Service employee spokespersons while acting in their official capacities. The Company is not responsible for any infringement of intellectual property rights or breach of any applicable law or regulation, including regulation in relation to financial services or the distribution of financial products, defamation, data protection, telecommunications (including regulations relating to excessive use, spamming or other abusive activities) or obscene, offensive or illegal content). Under no circumstances will the Company be liable for any loss or damage caused by a member's reliance on information obtained through the Service. It is the responsibility of member to evaluate the accuracy, completeness or usefulness of any information, opinion, advice or other content available through the Service. Please seek the advice of professionals, as appropriate, regarding the evaluation of any specific information, opinion, advice or other content.

Read the full Member Agreement
http://www.zawya.com/legal/NewsLetter.cfm?name=disclaimer
 
 
Access to this article is subject to specific terms and conditions. Read Disclaimer.
 
 
 
Community Comments (0) - Comment on this article
The opinions of the authors expressed herein do not necessarily state or reflect Zawya. Read our Comment Policy.
 
 
 
Loading ...
 
Report Abuse
Loading ...
 
 
Loading ...
Zawya Comment Policy:
 
  1. Zawya encourages you to add a comment to this discussion. You agree that when you add content to this discussion your comments will not:
    1.1   Contain any material which is libelous or defamatory of any person, is obscene, offensive, hateful or inflammatory or causes damage to the reputation of any person or organisation.
    1.2   Promote sexually explicit material, violence, discrimination based on race, sex, religion, nationality, disability, sexual orientation or age or any illegal activity.
    1.3   Be made in breach of any legal duty owed to a third party, such as a contractual duty or a duty of confidence.
    1.4   Be threatening, abuse or invade another's privacy, or cause annoyance, inconvenience or needless anxiety.
    1.5   Be used to impersonate any person, to misrepresent your identity or affiliation with any person, or be likely to deceive any person.
    1.6   Give the impression that they represent Zawya.
    1.7   Advocate, promote or assist any unlawful act such as (by way of example only) copyright infringement or computer misuse.
  2. The content posted on www.zawya.com is created by members of the public. The views expressed are theirs and unless specifically stated are not those of Zawya. Zawya reserves the right to review all comments prior to posting and edit or delete any contribution, but Zawya is not responsible for and can not be held liable for any content posted by members of the public on www.zawya.com.
  3. Zawya is not responsible for the availability or content of any third party sites that are accessible through www.zawya.com. Any links to third party websites from www.zawya.com do not amount to any endorsement of that site by Zawya and any use of that site by you is at your own risk.
  4. By submitting your comment, you hereby give Zawya the right, but not the obligation, to post, air, edit, exhibit, telecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comments worldwide, in perpetuity.
 
 
 
 
 
Community Buzz

Stories

Companies

Most viewed companies by Community in the last 24 hrs
Company Name Country Industry
Consolidated Contractors Company Overseas Construction and Design
Saudi Binladin Group Saudi Arabia Construction and Design
Saudi Telecom Saudi Arabia Telecommunications Services
Saudi Electricity Company Saudi Arabia Electric Utilities
Zuhair Fayez Partnership Consultants Saudi Arabia Construction and Design
Ministry of Health - Saudi Arabia Saudi Arabia Ministries and Municipalities
Qatar Engineering and Construction Company Qatar Construction and Design
Hyundai Engineering and Construction Company - Saudi Arabia Saudi Arabia Construction and Design
Nissan Motor Egypt Egypt Transportation Products
Almarai Company Saudi Arabia Food
 

Projects

Blogs

 
 

 
 
 
 
 

Site is optimised for viewing at 1024 x 768 with Internet Explorer v6 and Firefox v3.0 and above.
Copyright © 2010 ABQ Zawya Ltd. All rights reserved. Please read our Membership Agreement